Role of Heat Stable Fraction of Alkaline Phosphatase As an Adjunct to Ca 125 in Monitoring Patients of Epithelial Ovarian Carcinoma

Overview

Journal Indian J Clin Biochem

Specialty Biochemistry

Date 2012 Oct 30

PMID 23105532

Authors

P K Nigam

A Jain

P Goyal

R Chitra

Affiliations

Soon will be listed here.

Abstract

Heat stable fraction (HSF) of alkaline phosphatase (ALP) was evaluated as an adjunct to CA 125 as a tumour marker for epithelial ovarian cancer in a follow-up study. In our study group 63.4% of patients had elevated HSF levels (≥10U/L) and 93.3% had elevated CA 125 levels (>35U/mL). The sensitivity of CA 125 and HSF was 93.3% and 63.3% respectively. The decline in the activity of HSF, over the pre-op levels was highly significant after the first (p=0.001) chemotherapy cycle and significant after the second and third cycles (p<0.029). Thereafter, HSF activity was almost undetectable. The decrease in CA 125 levels over the pre-op levels was significant after the first, second, third (p<0.001) and fourth (p<0.034) chemotherapy cycle. HSF can be used alone or as an adjunct to CA 125 in screening and monitoring patients of ovarian carcinoma especially in remote areas where sophisticated facilities are not available and in patients in which CA 125 levels are not raised preoperatively.

References

Vergote I, Bormer O, Abeler V . Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol. 1987; 157(1):88-92. DOI: 10.1016/s0002-9378(87)80352-6. View

FISHMAN W, BARDAWIL W, Habib H, Anstiss C, Green S . The placental isoenzymes of alkaline phosphatase in sera of normal pregnancy. Am J Clin Pathol. 1972; 57(1):65-74. DOI: 10.1093/ajcp/57.1.65. View

Ward B, Cruickshank D, TUCKER D, Love S . Independent expression in serum of three tumour-associated antigens: CA 125, placental alkaline phosphatase and HMFG2 in ovarian carcinoma. Br J Obstet Gynaecol. 1987; 94(7):696-8. DOI: 10.1111/j.1471-0528.1987.tb03178.x. View

Haije W . Biochemical markers in ovarian cancer: possibilities and limitations. Ann Clin Biochem. 1982; 19 (Pt 4):258-62. DOI: 10.1177/000456328201900414. View

JOLY D, LILIENFELD A, Diamond E, Bross I . An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am J Epidemiol. 1974; 99(3):190-209. DOI: 10.1093/oxfordjournals.aje.a121603. View

Nozawa S, Udagawa Y, Ohkura H, Negishi Y, Akiya K, Inaba N . Serum placental alkaline phosphatase (PLAP) in gynecologic malignancies--with special reference to the combination of PLAP and CA54/61 assay. Clin Chim Acta. 1990; 186(2):275-84. DOI: 10.1016/0009-8981(90)90045-t. View

Beral V, Fraser P, Chilvers C . Does pregnancy protect against ovarian cancer?. Lancet. 1978; 1(8073):1083-7. DOI: 10.1016/s0140-6736(78)90925-x. View

Bast Jr R, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M . Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer. 1991; 68(8):1758-63. DOI: 10.1002/1097-0142(19911015)68:8<1758::aid-cncr2820680819>3.0.co;2-#. View

Tammela J, Lele S . New modalities in detection of recurrent ovarian cancer. Curr Opin Obstet Gynecol. 2004; 16(1):5-9. DOI: 10.1097/00001703-200402000-00003. View

10.

Nouwen E, Pollet D, Schelstraete J, Eerdekens M, HANSCH C, Van de Voorde A . Human placental alkaline phosphatase in benign and malignant ovarian neoplasia. Cancer Res. 1985; 45(2):892-902. View

11.

Thakur V, Anand A, Mukherjee U, Ghosh D . Determination of cancer antigen 125 in ovarian carcinoma. Indian J Clin Biochem. 2012; 18(2):27-33. PMC: 3453871. DOI: 10.1007/BF02867364. View